Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company d...
Beyond Air Inc. is a clinical-stage medical dev...
Neuronetics, Inc. is focused on designing, developing, and marketing products that...
Neuronetics, Inc. is focused on designing, deve...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Agenus is an immuno-oncology company designed to deliver innovation with speed for...
Agenus is an immuno-oncology company designed t...
IMAC Holdings, Inc. owns or manages IMAC Regeneration Centers, which combine life ...
IMAC Holdings, Inc. owns or manages IMAC Regene...
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
Cesca is a leading regenerative medicine company that develops, commercializes and...
Cesca is a leading regenerative medicine compan...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Join the National Investor Network and get the latest information with your interests in mind.